BBA
CELG

Braun-Bostich & Associates’s Celgene Corp CELG Stock Holding History

Braun-Bostich & Associates’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-136
Closed -$9K – 349
2018
Q4 		$9K Sell
136
-234
-63% -$17.3K 0.01% 261
2018
Q3 		$33K Hold
370
– – 0.03% 201
2018
Q2 		$29K Sell
370
-5,301
-93% -$440K 0.03% 200
2018
Q1 		$506K Buy
5,671
+440
+8% +$42.2K 0.44% 71
2017
Q4 		$546K Buy
+5,231
New +$590K 0.46% 67

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Braun-Bostich & Associates's CELG Position: Q1 2019 in Review

Braun-Bostich & Associates sold out of Celgene Corp (CELG) in Q1 2019, closing a stake of 136 shares — an estimated $9K sold.

Braun-Bostich & Associates first reported a position in CELG in Q4 2017 and held it in 5 quarters. The position peaked at $546K in Q4 2017. 1,389 funds tracked by Wall St. Rank hold CELG as of Q1 2019.

  • Braun-Bostich & Associates reported no remaining Celgene Corp position as of Q1 2019 after selling out during the quarter.
  • Braun-Bostich & Associates sold 136 Celgene Corp shares in Q1 2019, an estimated $9K.
  • Braun-Bostich & Associates first reported a position in Celgene Corp in Q4 2017 and held it in 5 quarters.
  • Braun-Bostich & Associates's Celgene Corp position peaked at $546K in Q4 2017.
  • 1,389 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2019.

Based on Braun-Bostich & Associates's 13F filing for Q1 2019, filed 9 May 2019.